{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:15:12Z","timestamp":1779099312565,"version":"3.51.4"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,4,21]],"date-time":"2014-04-21T00:00:00Z","timestamp":1398038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Health\u2010care stakeholders increasingly recognize that the scientific and economic challenges associated with Alzheimer's disease (AD) are simply too great for individual stakeholder groups to address solely from within their own silos. In the necessary spirit of collaboration, we present in this perspective a set of multicountry multistakeholder recommendations to improve the organization of existing AD and dementia care and the development of new treatments. In brief, the five recommendations are (1) health\u2010care systems must make choices regarding the patient populations to be diagnosed and treated, (2) health\u2010care systems should use an evidence\u2010based standard of care, (3) increased collaboration between public and private institutions is needed to enhance research, (4) reimbursement end points need to be agreed on and validated, and (5) innovative business models should be used to spur the introduction of new medicines.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.jalz.2014.01.007","type":"journal-article","created":{"date-parts":[[2014,4,21]],"date-time":"2014-04-21T02:48:00Z","timestamp":1398048480000},"page":"455-461","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease"],"prefix":"10.1002","volume":"11","author":[{"given":"Patrick","family":"Bradley","sequence":"first","affiliation":[{"name":"Tapestry Networks (US Office)  Waltham MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Akehurst","sequence":"additional","affiliation":[{"name":"School of Health &amp; Related Research (ScHARR) University of Sheffield  Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[{"name":"Wolfson Centre for Age Related Diseases King's College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sube","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Brighton &amp; Sussex Medical School University of Sussex  Brighton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[{"name":"Clinical Neurochemistry Laboratory Department of Psychiatry &amp; Neurochemistry Institute of Neuroscience &amp; Physiology The Sahlgrenska Academy at University of Gothenburg  M\u00f6lndal Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Bremner","sequence":"additional","affiliation":[{"name":"European Health Management Association (EHMA)  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Broich","sequence":"additional","affiliation":[{"name":"Federal Institute for Drugs &amp; Medical Devices (BfArM)  Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Cummings","sequence":"additional","affiliation":[{"name":"Lou Ruvo Center for Brain Health Cleveland Clinic  Las Vegas NV USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Dening","sequence":"additional","affiliation":[{"name":"Admiral Nursing Dementia UK  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Dubois","sequence":"additional","affiliation":[{"name":"Alzheimer Institute (IM2A) Salp\u00eatri\u00e8re University Hospital, UPMC  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiebke","family":"Klipper","sequence":"additional","affiliation":[{"name":"Pharmaceuticals Department Federal Joint Committee (G\u2010BA)  Berlin Germany"},{"name":"Biogen Idec  Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Leibman","sequence":"additional","affiliation":[{"name":"Biogen Idec  Cambridge MA USA"},{"name":"Janssen Alzheimer Immunotherapy Research &amp; Development LLC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Mantua","sequence":"additional","affiliation":[{"name":"Italian Medicines Agency (AIFA)  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Molinuevo","sequence":"additional","affiliation":[{"name":"Alzheimer's Disease and Other Cognitive Disorders Unit Barcelona Clinical Hospital  Barcelona Spain"},{"name":"Early Detection Programme Pasqual Maragall Foundation  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Morgan","sequence":"additional","affiliation":[{"name":"Medicines &amp; Healthcare Products Regulatory Agency (MHRA)  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa A.A.","family":"Muscolo","sequence":"additional","affiliation":[{"name":"Italian Medicines Agency (AIFA)  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Nicolas","sequence":"additional","affiliation":[{"name":"Sanofi S.A.  Paris France"},{"name":"PET Neurology, GE Healthcare"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Pani","sequence":"additional","affiliation":[{"name":"Italian Medicines Agency (AIFA)  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Robinson","sequence":"additional","affiliation":[{"name":"Primary Care &amp; Ageing, Institute of Health and Society Newcastle University  Newcastle upon Tyne UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Siviero","sequence":"additional","affiliation":[{"name":"Italian Medicines Agency (AIFA)  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius","family":"van Dam","sequence":"additional","affiliation":[{"name":"Independent Consultant in Reimbursement &amp; Pharmacy  Zwolle Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"VanEmelen","sequence":"additional","affiliation":[{"name":"Association Internationale de la Mutualit\u00e9  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Wimo","sequence":"additional","affiliation":[{"name":"Alzheimer's Disease Research Centre Karolinska Institutet  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Wortmann","sequence":"additional","affiliation":[{"name":"Alzheimer's Disease International (ADI)  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindee","family":"Goh","sequence":"additional","affiliation":[{"name":"Tapestry Networks (US Office)  Waltham MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,4,21]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.11.006"},{"key":"e_1_2_5_3_1","volume-title":"Dementia: a public health priority","author":"World Health Organization and Alzheimer's Disease International","year":"2012"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70178-3"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70223-4"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.003"},{"key":"e_1_2_5_10_1","unstructured":"European Healthcare Innovation Leadership Network \u201cAlzheimer's Disease Working Group Launch Meeting: setting the agenda for change \u201d 14 June2012. Available athttp:\/\/www.tapestrynetworks.com\/initiatives\/healthcare\/Alzheimers\u2010disease.cfm. Accessed July 9 2013."},{"key":"e_1_2_5_11_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nj7371-139a","article-title":"Biomarkers on the brain","volume":"479","author":"Katsnelson A","year":"2011","journal-title":"Nature"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2009.217"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.4"},{"key":"e_1_2_5_14_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2967\/jnumed.113.120618","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association","volume":"54","author":"Johnson KA","year":"2013","journal-title":"J Nucl Med"},{"key":"e_1_2_5_15_1","first-page":"7","volume-title":"Living well with dementia: a National Dementia Strategy","author":"Department of Health","year":"2009"},{"key":"e_1_2_5_16_1","unstructured":"European Healthcare Innovation Leadership Network.Alzheimer's Disease Working Group: advancing progress in the face of dynamic science and constrained resources 2012. Available athttp:\/\/www.tapestrynetworks.com\/initiatives\/healthcare\/Alzheimers\u2010disease.cfm. Accessed July 9 2013."},{"key":"e_1_2_5_17_1","volume-title":"Dementia: supporting people with dementia and their carers in health and social care","author":"National Institute for Health and Clinical Excellence (NICE) and Social Care Institute for Excellence (SCIE)","year":"2007"},{"key":"e_1_2_5_18_1","unstructured":"Glaxo Smith Kline.GSK announces further initiatives to advance openness and collaboration to help tackle global health challenges. Available at:http:\/\/www.gsk.com\/media\/press\u2010releases\/2012\/GSK\u2010announces\u2010further\u2010initiatives\u2010to\u2010tackle\u2010global\u2010health\u2010challenges.html. Accessed July 9 2013."},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001202"},{"key":"e_1_2_5_20_1","unstructured":"European Medicines Agency.Release of data from clinical trials. Available at:http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/special_topics\/general\/general_content_000555.jsp&mid=WC0b01ac0580607bfa. Accessed July 9 2013."},{"key":"e_1_2_5_21_1","unstructured":"Alzheimer's Disease Neuroimaging Initiative.Welcome from the ADNI Principal Investigator. Available at:http:\/\/www.adni\u2010info.org\/. Accessed July 9 2013."},{"key":"e_1_2_5_22_1","unstructured":"Critical Path Institute.Coalition Against Major Diseases. Available at:http:\/\/c\u2010path.org\/programs\/camd\/. Accessed March 27 2014."},{"key":"e_1_2_5_23_1","first-page":"13","volume-title":"Researching Alzheimer's medicines: setbacks and stepping stones","author":"PhRMA","year":"2012"},{"key":"e_1_2_5_24_1","volume-title":"Alzheimer's disease: developing drugs for the treatment of early stage disease (draft guidance for industry)","author":"Food and Drug Administration's Center for Drug Evaluation and Research","year":"2013"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1302513"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526014000338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526014000338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.jalz.2014.01.007","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2014.01.007","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1016\/j.jalz.2014.01.007","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2014.01.007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T17:27:22Z","timestamp":1759858042000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1016\/j.jalz.2014.01.007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,21]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1016\/j.jalz.2014.01.007"],"URL":"https:\/\/doi.org\/10.1016\/j.jalz.2014.01.007","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,21]]},"assertion":[{"value":"2014-04-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}